Aptamer applications for targeted cancer therapy

Future Oncology

Volumn 6, Issue 7, 2010, Pages 1117-1126

  Barbas, Andrew S ^a   Mi, Jing ^a   Clary, Bryan M ^a   White, Rebekah R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

aptamer; nanoparticle SELEX; siRNA; targeted therapy

Indexed keywords

AGRO 100; ANTIINFECTIVE AGENT; APTAMER; AS 1411; CELL SURFACE PROTEIN; CYTOTOXIN; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN MU CHAIN; LIGAND; MEMBRANE PROTEIN; MUCIN 1; NANOPARTICLE; NUCLEOLIN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROTEIN P68; PROTEIN RET; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE 7; RNA; SINGLE STRANDED DNA; SMALL INTERFERING RNA; TENASCIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 3; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

CANCER CELL CULTURE; CANCER THERAPY; CELL SURFACE; COMBINATORIAL CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG TARGETING; HUMAN; MICELLE; NONHUMAN; PRIORITY JOURNAL; REVIEW; NEOPLASMS;

ANTINEOPLASTIC AGENTS; APTAMERS, NUCLEOTIDE; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS; SELEX APTAMER TECHNIQUE;

EID: 77954678126     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.10.67     Document Type: Review

References (57)

1. Perkins AC, Missailidis S: Radiolabelled aptamers for tumour imaging and therapy. Q. J. Nucl. Med. Mol. Imaging 51(4), 292-296 (2007).
2. Ireson CR, Kelland LR: Discovery and development of anticancer aptamers. Mol. Cancer Ther. 5(12), 2957-2962 (2006).
3. Proske D, Blank M, Buhmann R, Resch A: Aptamers - basic research, drug development, and clinical applications. Appl. Microbiol. Biotechnol. 69(4), 367-374 (2005).
4. Knudsen SM, Robertson MP, Ellington AD: In vitro selection using modified or unnatural nucleotides. Curr. Protoc. Nucleic Acid Chem. Chapter 9, Unit 9.6 (2002).
5. Levy-Nissenbaum E, Radovic-Moreno AF, Wang AZ, Langer R, Farokhzad OC: Nanotechnology and aptamers: applications in drug delivery. Trends Biotechnol. 26(8), 442-449 (2008).
6. Phillips JA, Lopez-Colon D, Zhu Z, Xu Y, Tan W: Applications of aptamers in cancer cell biology. Anal. Chim. Acta 621(2), 101-108 (2008).
7. Healy JM, Lewis SD, Kurz M, et al.: Pharmacokinetics and biodistribution of novel aptamer compositions. Pharm. Res. 21(12), 2234-2246 (2004).
8. Ellington AD, Szostak JW: In vitro selection of RNA molecules that bind specific ligands. Nature 346(6287), 818-822 (1990).
9. Tuerk C, Gold L: Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage t4 DNA polymerase. Science 249(4968), 505-510 (1990).
10. White RR, Shan S, Rusconi CP, et al.: Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2. Proc. Natl Acad. Sci. USA 100(9), 5028-5033 (2003).
11. Sarraf-Yazdi S, Mi J, Moeller BJ, et al.: Inhibition of in vivo tumor angiogenesis and growth via systemic delivery of an angiopoietin 2-specific RNA aptamer. J. Surg. Res. 146(1), 16-23 (2008).
12. Mi Z, Guo H, Russell MB, Liu Y, Sullenger BA, Kuo PC: RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-mb231 breast cancer cells. Mol. Ther. 17(1), 153-161 (2009).
13. Sennino B, Falcon BL, Mccauley D, et al.: Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of platelet-derived growth factor B by selective aptamer AX102. Cancer Res. 67(15), 7358-7367 (2007).
14. Verhoeff JJ, Stalpers LJ, Claes A, et al.: Tumour control by whole brain irradiation of anti-VEGF-treated mice bearing intracerebral glioma. Eur. J. Cancer 45(17), 3074-3080 (2009).
15. White RR, Sullenger BA, Rusconi CP: Developing aptamers into therapeutics. J. Clin. Invest. 106(8), 929-934 (2000).
16. Mallikaratchy P, Tang Z, Kwame S, Meng L, Shangguan D, Tan W: Aptamer directly evolved from live cells recognizes membrane bound immunoglobin heavy ? chain in Burkitts lymphoma cells. Mol. Cell Proteomics 6(12), 2230-2238 (2007)
17. Shangguan D, Cao Z, Meng L, et al.: Cell-specific aptamer probes for membrane protein elucidation in cancer cells. J. Proteome Res. 7(5), 2133-2139 (2008).
18. Ferreira CS, Matthews CS, Missailidis S: DNA aptamers that bind to MUC1 tumour marker: design and characterization of MUC1-binding single-stranded DNA aptamers. Tumour Biol. 27(6), 289-301 (2006).
19. Ferreira CS, Cheung MC, Missailidis S, Bisland S, Gariepy J: Phototoxic aptamers selectively enter and kill epithelial cancer cells. Nucleic Acids Res. 37(3), 866-876 (2009).
20. Lupold SE, Hicke BJ, Lin Y, Coffey DS: Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res. 62(14), 4029-4033 (2002).
21. Wang SC, Hung MC: Nuclear translocation of the epidermal growth factor receptor family membrane tyrosine kinase receptors. Clin. Cancer Res. 15(21), 6484-6489 (2009).
22. Li N, Larson T, Nguyen HH, Sokolov KV, Ellington AD: Directed evolution of gold nanoparticle delivery to cells. Chem. Commun. (Camb.) 46(3), 392-394 (2010).
23. Shamah SM, Healy JM, Cload ST: Complex target SELEX. Acc. Chem. Res. 41(1), 130-138 (2008).
24. Guo KT, Paul A, Schichor C, Ziemer G, Wendel HP: Cell-SELEX: novel perspectives of aptamer-based therapeutics. Int. J. Mol. Sci. 9(4), 668-678 (2008).
25. Cerchia L, Duconge F, Pestourie C, et al.: Neutralizing aptamers from whole-cell SELEX inhibit the ret receptor tyrosine kinase. PLoS Biol. 3(4), E123 (2005).
26. Ohuchi SP, Ohtsu T, Nakamura Y: A novel method to generate aptamers against recombinant targets displayed on the cell surface. Nucleic Acids Symp. Ser. (Oxf.) 49, 351-352 (2005).
27. Ohuchi SP, Ohtsu T, Nakamura Y: Selection of RNA aptamers against recombinant transforming growth factor-b type III receptor displayed on cell surface. Biochimie 88(7), 897-904 (2006).
28. Daniels DA, Chen H, Hicke BJ, Swiderek KM, Gold L: A tenascin-C aptamer identified by tumor cell SELEX: systematic evolution of ligands by exponential enrichment. Proc. Natl Acad. Sci. USA 100(26), 15416-15421 (2003).
29. Blank M, Weinschenk T, Priemer M, Schluesener H: Systematic evolution of a DNA aptamer binding to rat brain tumor microvessels. Selective targeting of endothelial regulatory protein pigpen. J. Biol. Chem. 276(19), 16464-16468 (2001).
30. Cerchia L, Esposito CL, Jacobs AH, Tavitian B, De Franciscis V: Differential SELEX in human glioma cell lines. PLoS ONE 4(11), E7971 (2009).
31. Chen HW, Medley CD, Sefah K, et al.: Molecular recognition of small-cell lung cancer cells using aptamers. ChemMedChem 3(6), 991-1001 (2008).
32. Hicke BJ, Marion C, Chang YF, et al.: Tenascin-C aptamers are generated using tumor cells and purified protein. J. Biol. Chem. 276(52), 48644-48654 (2001).
33. Shangguan D, Cao ZC, Li Y, Tan W: Aptamers evolved from cultured cancer cells reveal molecular differences of cancer cells in patient samples. Clin. Chem. 53(6), 1153-1155 (2007).
34. Shangguan D, Meng L, Cao ZC, et al.: Identification of liver cancer-specific aptamers using whole live cells. Anal. Chem. 80(3), 721-728 (2008).
35. Tang Z, Shangguan D, Wang K, et al.: Selection of aptamers for molecular recognition and characterization of cancer cells. Anal. Chem. 79(13), 4900-4907 (2007).
36. Hicke BJ, Stephens AW, Gould T, et al.: Tumor targeting by an aptamer. J. Nucl. Med. 47(4), 668-678 (2006).
37. Mi J, Liu Y, Rabbani ZN, et al.: In vivo selection of tumor-targeting RNA motifs. Nat. Chem. Biol. 6(1), 22-24 (2010).
38. Rossow KL, Janknecht R: Synergism between p68 RNA helicase and the transcriptional coactivators CBP and P300. Oncogene 22(1), 151-156 (2003).
39. Shin S, Rossow KL, Grande JP, Janknecht R: Involvement of RNA helicases p68 and p72 in colon cancer. Cancer Research 67(16), 7572-7578 (2007).
40. Bates PJ, Laber DA, Miller DM, Thomas SD, Trent JO: Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp. Mol. Pathol. 86(3), 151-164 (2009).
41. Soundararajan S, Chen W, Spicer EK, Courtenay-Luck N, Fernandes DJ: The nucleolin targeting aptamer as1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells. Cancer Res. 68(7), 2358-2365 (2008).
42. Chu TC, Twu KY, Ellington AD, Levy M: Aptamer mediated siRNA delivery. Nucleic Acids Res. 34(10), E73 (2006).
43. McNamara JO 2nd, Andrechek ER, Wang Y, et al.: Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat. Biotechnol. 24(8), 1005-1015 (2006).
44. Dassie JP, Liu XY, Thomas GS, et al.: Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat. Biotechnol. 27(9), 839-849 (2009).
45. Wullner U, Neef I, Eller A, Kleines M, Tur MK, Barth S: Cell-specific induction of apoptosis by rationally designed bivalent aptamer-siRNA transcripts silencing eukaryotic elongation factor 2. Curr. Cancer Drug Targets 8(7), 554-565 (2008).
46. Chu TC, Marks JW 3rd, Lavery LA, et al.: Aptamer:toxin conjugates that specifically target prostate tumor cells. Cancer Res. 66(12), 5989-5992 (2006).
47. Bagalkot V, Farokhzad OC, Langer R, Jon S: An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform. Angew. Chem. Int. Ed. Engl. 45(48), 8149-8152 (2006).
48. Bagalkot V, Zhang L, Levy-Nissenbaum E, et al.: Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. Nano. Lett. 7(10), 3065-3070 (2007).
49. Cheng J, Teply BA, Sherifi I, et al.: Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials 28(5), 869-876 (2007).
50. Farokhzad OC, Cheng J, Teply BA, et al.: Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc. Natl Acad. Sci. USA 103(16), 6315-6320 (2006).
51. Zhang L, Radovic-Moreno AF, Alexis F, et al.: Co-delivery of hydrophobic and hydrophilic drugs from nanoparticle-aptamer bioconjugates. ChemMedChem 2(9), 1268-1271 (2007).
52. Dhar S, Gu FX, Langer R, Farokhzad OC, Lippard SJ: Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc. Natl Acad. Sci. USA 105(45), 17356-17361 (2008).
53. Wang AZ, Bagalkot V, Vasilliou CC, et al.: Superparamagnetic iron oxide nanoparticle- aptamer bioconjugates for combined prostate cancer imaging and therapy. ChemMedChem 3(9), 1311-1315 (2008).
54. Huang YF, Sefah K, Bamrungsap S, Chang HT, Tan W: Selective photothermal therapy for mixed cancer cells using aptamer-conjugated nanorods. Langmuir 24(20), 11860-11865 (2008).
55. Huang YF, Shangguan D, Liu H, et al.: Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells. ChemBioChem 10(5), 862-868 (2009).
56. Hwang Do W, Ko HY, Lee JH, et al.: A nucleolin-targeted multimodal nanoparticle imaging probe for tracking cancer cells using an aptamer. J. Nucl. Med. 51(1), 98-105 (2010).
57. Wu Y, Sefah K, Liu H, Wang R, Tan W: DNA aptamer-micelle as an efficient detection/delivery vehicle toward cancer cells. Proc. Natl Acad. Sci. USA 107(1), 5-10 (2010).